JP2024016207A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024016207A5 JP2024016207A5 JP2023191314A JP2023191314A JP2024016207A5 JP 2024016207 A5 JP2024016207 A5 JP 2024016207A5 JP 2023191314 A JP2023191314 A JP 2023191314A JP 2023191314 A JP2023191314 A JP 2023191314A JP 2024016207 A5 JP2024016207 A5 JP 2024016207A5
- Authority
- JP
- Japan
- Prior art keywords
- fab
- liquid suspension
- hvegf
- eye
- raav
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006194 liquid suspension Substances 0.000 claims 31
- 241000702421 Dependoparvovirus Species 0.000 claims 14
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 claims 10
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 10
- 206010064930 age-related macular degeneration Diseases 0.000 claims 10
- 230000001105 regulatory effect Effects 0.000 claims 7
- 108091026890 Coding region Proteins 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 210000000234 capsid Anatomy 0.000 claims 6
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 229960003876 ranibizumab Drugs 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- 102000007469 Actins Human genes 0.000 claims 2
- 108010085238 Actins Proteins 0.000 claims 2
- 241001164825 Adeno-associated virus - 8 Species 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 2
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 2
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 2
- 102100037935 Polyubiquitin-C Human genes 0.000 claims 2
- 108010056354 Ubiquitin C Proteins 0.000 claims 2
- 102000018358 immunoglobulin Human genes 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 241000702423 Adeno-associated virus - 2 Species 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 claims 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010025421 Macule Diseases 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 208000002352 blister Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 229920001983 poloxamer Polymers 0.000 claims 1
- 230000008488 polyadenylation Effects 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862632775P | 2018-02-20 | 2018-02-20 | |
| US62/632,775 | 2018-02-20 | ||
| US201862663532P | 2018-04-27 | 2018-04-27 | |
| US62/663,532 | 2018-04-27 | ||
| JP2020543914A JP2021516671A (ja) | 2018-02-20 | 2019-02-19 | 滲出型加齢性黄斑変性の治療のための組成物 |
| PCT/US2019/018640 WO2019164854A1 (en) | 2018-02-20 | 2019-02-19 | Compositions for treatment of wet age-related macular degeneration |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543914A Division JP2021516671A (ja) | 2018-02-20 | 2019-02-19 | 滲出型加齢性黄斑変性の治療のための組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024016207A JP2024016207A (ja) | 2024-02-06 |
| JP2024016207A5 true JP2024016207A5 (https=) | 2024-08-13 |
Family
ID=67688300
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543914A Pending JP2021516671A (ja) | 2018-02-20 | 2019-02-19 | 滲出型加齢性黄斑変性の治療のための組成物 |
| JP2023191314A Pending JP2024016207A (ja) | 2018-02-20 | 2023-11-09 | 滲出型加齢性黄斑変性の治療のための組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543914A Pending JP2021516671A (ja) | 2018-02-20 | 2019-02-19 | 滲出型加齢性黄斑変性の治療のための組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12558434B2 (https=) |
| EP (1) | EP3755804A4 (https=) |
| JP (2) | JP2021516671A (https=) |
| KR (1) | KR20210022524A (https=) |
| AU (2) | AU2019223963A1 (https=) |
| CA (1) | CA3090293A1 (https=) |
| IL (1) | IL276777B2 (https=) |
| MA (1) | MA51916A (https=) |
| SG (1) | SG11202007252VA (https=) |
| WO (1) | WO2019164854A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11223668B2 (en) * | 2017-01-12 | 2022-01-11 | Telefonaktiebolaget Lm Ericsson (Publ) | Anomaly detection of media event sequences |
| EP3687464A4 (en) * | 2017-09-27 | 2021-09-29 | REGENXBIO Inc. | TREATMENT OF EYE DISEASES WITH A TOTALLY HUMAN POST-TRANSLATION MODIFIED ANTI-VEGF FAB |
| EP3727468A4 (en) | 2017-12-19 | 2021-09-22 | Akouos, Inc. | AAV-MEDIATED THERAPEUTIC ANTIBODIES DELIVERY TO THE INTERNAL EAR |
| US11360969B2 (en) | 2019-03-20 | 2022-06-14 | Promethium, Inc. | Natural language based processing of data stored across heterogeneous data sources |
| WO2021046245A1 (en) * | 2019-09-04 | 2021-03-11 | University Of Massachusetts | Adeno-associated virus vector platform for delivery of kh902 (conbercept) and uses thereof |
| IL295673A (en) * | 2020-02-28 | 2022-10-01 | Univ Pennsylvania | Treatment of autosomal dominant strophin diseases and methods of their evaluation |
| US20230152336A1 (en) * | 2020-04-24 | 2023-05-18 | Siemens Healthcare Diagnostics Inc. | Calibration and quality control reagents for use with immunoassays for antibodies and methods of production and use thereof |
| WO2021255590A1 (en) * | 2020-06-16 | 2021-12-23 | Intas Pharmaceuticals Ltd. | An anti-vegf scfv adeno-associated virus (aav) vector and uses thereof |
| WO2021255589A1 (en) * | 2020-06-16 | 2021-12-23 | Intas Pharmaceuticals Ltd. | An anti-vegf scfab adeno-associated virus (aav) vector and uses thereof |
| CR20230202A (es) | 2020-10-16 | 2023-06-13 | Gyroscope Therapeutics Ltd | Ácido nucleico que codifica una entidad anti-vegf y un regulador del complemento negativo y sus usos para el tratamiento de la degeneración macular relacionada con la edad |
| IL303317A (en) * | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| WO2022165313A1 (en) | 2021-02-01 | 2022-08-04 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
| US20240335562A1 (en) * | 2021-08-04 | 2024-10-10 | Alpine Biotherapeutics Corporation | Sustainable ocular cell-mediated intraocular delivery of cellular therapeutics for treatment of ocular diseases or disorders |
| CN114181972A (zh) * | 2021-11-23 | 2022-03-15 | 上海本导基因技术有限公司 | 适用于难治性血管新生性眼疾病基因治疗的慢病毒载体 |
| KR102789747B1 (ko) * | 2021-12-29 | 2025-04-03 | 한국과학기술원 | Prox1 단백질에 중화 활성을 갖는 결합 분자 |
| TW202342525A (zh) * | 2022-02-02 | 2023-11-01 | 美商阿科奧斯公司 | 用於治療前庭神經鞘瘤相關症狀之抗ｖｅｇｆ抗體構築體及相關方法 |
| WO2023236964A1 (zh) * | 2022-06-07 | 2023-12-14 | 成都弘基生物科技有限公司 | 腺相关病毒药物组合物及其用途 |
| WO2024238859A1 (en) * | 2023-05-16 | 2024-11-21 | Regenxbio Inc. | Vectorized c5 inhibitor agents and administration thereof |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0804561B1 (en) | 1993-02-12 | 2009-12-30 | The Board Of Trustees Of The Leland Stanford Junior University | Regulated transcription of targeted genes and other biological events |
| AU719001B2 (en) | 1994-12-29 | 2000-05-04 | Massachusetts Institute Of Technology | Chimeric DNA-binding proteins |
| WO1996041865A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamcycin-based regulation of biological events |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| JP2003524368A (ja) | 1997-08-26 | 2003-08-19 | アリアド ジーン セラピューティクス インコーポレイテッド | ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白 |
| JP2001514007A (ja) | 1997-08-27 | 2001-09-11 | アリアド ジーン セラピューティクス インコーポレイテッド | キメラ転写アクチベーター、ならびにそれに関連する組成物および使用 |
| JP2002508971A (ja) | 1998-01-15 | 2002-03-26 | アリアド・ジーン・セラピューティクス・インコーポレーテッド | 多量体キメラ蛋白質を使用する生物学的イベントの調節 |
| JP2002503667A (ja) | 1998-02-13 | 2002-02-05 | プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 新規な二量体化剤、その製造および使用 |
| CA2379166C (en) | 1999-08-09 | 2013-03-26 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs |
| US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
| BR0014945A (pt) | 1999-10-21 | 2004-08-31 | Monsanto Co | Modificação pós-traducional de proteìnas recombinantes produzidas em plantas |
| GB2362884A (en) | 2000-05-30 | 2001-12-05 | Isis Innovation | Extended duration of airway gene therapy |
| CN1461342A (zh) | 2000-07-26 | 2003-12-10 | 路德维格癌症研究所 | 糖基化vegf－b和增加可溶性vegf－b量的方法 |
| MX359371B (es) | 2001-11-13 | 2018-09-25 | Univ Pennsylvania | Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo. |
| PT1453547T (pt) | 2001-12-17 | 2016-12-28 | Univ Pennsylvania | Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas |
| WO2003068801A2 (en) | 2002-02-11 | 2003-08-21 | Genentech, Inc. | Antibody variants with faster antigen association rates |
| US20040208847A1 (en) | 2003-03-28 | 2004-10-21 | Fabienne Rolling | Method and vectors for selectively transducing retinal pigment epithelium cells |
| EP2345731B1 (en) | 2003-09-30 | 2015-10-21 | The Trustees of the University of Pennsylvania | Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof |
| ES2525067T3 (es) | 2005-04-07 | 2014-12-17 | The Trustees Of The University Of Pennsylvania | Método de incremento de la función de un vector de AAV |
| JP4495210B2 (ja) | 2005-06-09 | 2010-06-30 | パナソニック株式会社 | 振幅誤差補償装置及び直交度誤差補償装置 |
| ES2533266T5 (es) | 2007-10-30 | 2018-04-18 | Genentech, Inc. | Purificación de anticuerpos mediante cromatografía de intercambio catiónico |
| TWI468417B (zh) | 2007-11-30 | 2015-01-11 | Genentech Inc | 抗－ｖｅｇｆ抗體 |
| KR101010352B1 (ko) | 2008-05-30 | 2011-01-25 | 삼성중공업 주식회사 | 전력 제어 장치 및 방법 |
| CA2742969A1 (en) | 2008-11-07 | 2010-05-14 | Fabrus Llc | Anti-dll4 antibodies and uses thereof |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| EP2443150B1 (en) * | 2009-06-17 | 2015-01-21 | AbbVie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
| US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| WO2012057363A1 (ja) | 2010-10-27 | 2012-05-03 | 学校法人自治医科大学 | 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン |
| WO2012109570A1 (en) | 2011-02-10 | 2012-08-16 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
| CN105755044A (zh) | 2011-04-22 | 2016-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| EP2559443A1 (en) | 2011-08-16 | 2013-02-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject |
| ES2857773T5 (es) | 2011-08-24 | 2024-06-04 | Univ Leland Stanford Junior | Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos |
| US20130090375A1 (en) | 2011-10-06 | 2013-04-11 | Cornell University | Virus-mediated delivery of bevacizumab for therapeutic applications |
| WO2013170078A1 (en) | 2012-05-09 | 2013-11-14 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
| TWI698240B (zh) | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| MX373894B (es) | 2012-11-08 | 2020-07-09 | Clearside Biomedical Inc | Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos. |
| US9567376B2 (en) | 2013-02-08 | 2017-02-14 | The Trustees Of The University Of Pennsylvania | Enhanced AAV-mediated gene transfer for retinal therapies |
| CA2905952A1 (en) | 2013-03-13 | 2014-10-02 | The Children's Hospital Of Philadelphia | Adeno-associated virus vectors and methods of use thereof |
| AU2014235096B2 (en) | 2013-03-15 | 2020-03-19 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating MPSI |
| ES2739288T3 (es) | 2013-09-13 | 2020-01-30 | California Inst Of Techn | Recuperación selectiva |
| CN106232618A (zh) | 2013-10-11 | 2016-12-14 | 马萨诸塞眼科耳科诊所 | 预测祖先病毒序列的方法及其用途 |
| JP6818551B2 (ja) | 2013-12-03 | 2021-01-20 | ホオキパ バイオテック ジーエムビーエイチ | Ｃｍｖワクチン |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| EP3134431B1 (en) | 2014-04-25 | 2021-04-07 | The Trustees Of The University Of Pennsylvania | Ldlr variants and their use in compositions for reducing cholesterol levels |
| WO2015164757A1 (en) | 2014-04-25 | 2015-10-29 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| ES2833230T3 (es) | 2014-05-13 | 2021-06-14 | Univ Pennsylvania | Composiciones que comprenden AVV que expresan construcciones y usos de doble anticuerpo del mismo |
| EP3151866B1 (en) | 2014-06-09 | 2023-03-08 | Voyager Therapeutics, Inc. | Chimeric capsids |
| US10064752B2 (en) | 2014-09-11 | 2018-09-04 | Orbit Biomedical Limited | Motorized suprachoroidal injection of therapeutic agent |
| AU2016219789B2 (en) | 2015-02-20 | 2021-03-25 | Fondazione Telethon | Methods and compositions for treating genetic eye diseases |
| EA201792500A1 (ru) | 2015-05-13 | 2018-04-30 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Aav-опосредованная экспрессия антител против гриппа и способы их использования |
| AU2016315703A1 (en) | 2015-08-31 | 2018-03-08 | The Trustees Of The University Of Pennsylvania | Chimeric AAV-anti-VEGF for treating cancer in canines |
| GB201519086D0 (en) | 2015-10-28 | 2015-12-09 | Syncona Partners Llp | Gene Therapy |
| CA3010862A1 (en) | 2016-01-08 | 2017-07-13 | Clearside Biomedical, Inc. | Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics |
| KR20240005973A (ko) | 2016-04-15 | 2024-01-12 | 리젠엑스바이오 인크. | 완전히-인간형의 번역후 변형된 항-VEGF Fab를 이용한 눈 질환의 치료 |
| SG11201808426XA (en) * | 2016-04-15 | 2018-10-30 | Univ Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| EP3687464A4 (en) | 2017-09-27 | 2021-09-29 | REGENXBIO Inc. | TREATMENT OF EYE DISEASES WITH A TOTALLY HUMAN POST-TRANSLATION MODIFIED ANTI-VEGF FAB |
| WO2020206098A1 (en) | 2019-04-03 | 2020-10-08 | Regenxbio Inc. | Gene therapy for eye pathologies |
-
2019
- 2019-02-18 US US16/971,215 patent/US12558434B2/en active Active
- 2019-02-19 KR KR1020207026455A patent/KR20210022524A/ko active Pending
- 2019-02-19 MA MA051916A patent/MA51916A/fr unknown
- 2019-02-19 CA CA3090293A patent/CA3090293A1/en active Pending
- 2019-02-19 EP EP19757101.1A patent/EP3755804A4/en active Pending
- 2019-02-19 AU AU2019223963A patent/AU2019223963A1/en not_active Abandoned
- 2019-02-19 WO PCT/US2019/018640 patent/WO2019164854A1/en not_active Ceased
- 2019-02-19 IL IL276777A patent/IL276777B2/en unknown
- 2019-02-19 SG SG11202007252VA patent/SG11202007252VA/en unknown
- 2019-02-19 JP JP2020543914A patent/JP2021516671A/ja active Pending
-
2023
- 2023-11-09 JP JP2023191314A patent/JP2024016207A/ja active Pending
-
2025
- 2025-06-25 AU AU2025204780A patent/AU2025204780A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024016207A5 (https=) | ||
| JP2022153418A5 (https=) | ||
| JP2021516671A5 (https=) | ||
| KR102616820B1 (ko) | 향상된 유전자 발현을 위한 조성물 및 방법 | |
| JP2025000642A5 (https=) | ||
| JP2021503914A5 (https=) | ||
| JP2019518427A5 (https=) | ||
| FI3717636T3 (fi) | Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä | |
| JP2020510424A5 (https=) | ||
| JP2022552262A5 (https=) | ||
| RU2018142768A (ru) | Варианты капсидов аденоассоциированного вируса и способы их применения | |
| US20200297869A1 (en) | Sequential intravitreal administration of aav gene therapy to contralateral eyes | |
| JP2023545424A5 (https=) | ||
| JP2022545967A5 (https=) | ||
| JP2011512417A (ja) | 血管形成の阻害 | |
| JP2022522776A5 (https=) | ||
| EP4549459A1 (en) | Aav drug for treating angiogenesis-related fundus diseases | |
| US20130090375A1 (en) | Virus-mediated delivery of bevacizumab for therapeutic applications | |
| KR20240150793A (ko) | Vegf 결합 분자 및 이의 의약적 용도 | |
| JP2023545229A5 (https=) | ||
| KR20240116840A (ko) | 변형된 aav 캡시드 단백질 및 이의 용도 | |
| AU2024261900A1 (en) | Nucleic acid encoding anti-vegf protein, polynucleotide expression cassette and recombinant adeno-associated virus | |
| CN117242183A (zh) | 用于治疗与血管生成相关的眼部疾病的组合物和方法 | |
| US20240279324A1 (en) | Multispecific antagonists | |
| CN117736274A (zh) | 一种腺相关病毒衣壳蛋白及其用途 |